Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
A new perspective on the design of molecular therapeutics is emerging. This new strategy emphasizes the rational complementation of functionality along extended patches of a protein surface with the aim of inhibiting protein/protein interactions. The successful development of compounds able to inhibit these interactions offers a unique chance to selectively intervene in a large number of key cellular processes related to human disease. Protein Surface Recognition presents a detailed treatment of this strategy, with topics including: * an extended survey of protein-protein interactions that are…mehr
A new perspective on the design of molecular therapeutics is emerging. This new strategy emphasizes the rational complementation of functionality along extended patches of a protein surface with the aim of inhibiting protein/protein interactions. The successful development of compounds able to inhibit these interactions offers a unique chance to selectively intervene in a large number of key cellular processes related to human disease. Protein Surface Recognition presents a detailed treatment of this strategy, with topics including: * an extended survey of protein-protein interactions that are key players in human disease and biology and the potential for therapeutics derived from this new perspective * the fundamental physical issues that surround protein-protein interactions that must be considered when designing ligands for protein surfaces * examples of protein surface-small molecule interactions, including treatments of protein-natural product interactions, protein-interface peptides, and rational approaches to protein surface recognition from model to biological systems * a survey of techniques that will be integral to the discovery of new small molecule protein surface binders, from high throughput synthesis and screening techniques to in silico and in vitro methods for the discovery of novel protein ligands. Protein Surface Recognition provides an intellectual "tool-kit" for investigators in medicinal and bioorganic chemistry looking to exploit this emerging paradigm in drug discovery.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
ERNEST GIRALT, Department of Organic Chemistry, University of Barcelona and Institute for Research in Biomedicine, Barcelona, Spain MARK PECZUH, Department of Chemistry, University of Connecticut, USA XAVIER SALVATELLA, ICREA and Institute for Research in Biomedicine, Barcelona, Spain
Inhaltsangabe
Preface. List of Contributors. PART I PRINCIPLES. 1 The Discovery and Characterization of Protein-Protein Interactions (C.W. Bertoncini, A. Higueruelo, and X. Salvatella). 1.1 Introduction. 1.2 Techniques to Identify Protein-Protein Interactions. 1.3 Techniques to Characterize Protein-Protein Interactions. 1.4 Structure and Dynamics of Protein Complexes. 1.5 Protein-Protein Complexes as Therapeutic Targets. 1.6 Conclusions. References. 2 Biophysics of Protein-Protein Interactions (Irene Luque). 2.1 Introduction. 2.2 Intermolecular Forces in Protein Recognition. 2.3 Basic Binding Thermodynamics. 2.4 Thermodynamically Driven Drug Design. 2.5 Measurement of Binding Energetics. 2.6 Structure-based Calculation of Protein Binding Energetics. 2.7 Interfacial Water Molecules in Protein Recognition. 2.8 The Linkage Between Binding and Conformational Equilibrium in Proteins. References. PART II APPROACHES. 3 On the Logic of Natural Product Binding in Protein-Protein Interactivity (James J. La Clair). 3.1 Introduction. 3.2 Structural Logic. 3.3 Functional Logic. 3.4 The Need for Programmers. 3.5 Compiling the NPPI Mapper. References. 4 Interface peptide inhibitors of PPIs (Mark W. Peczuh, and Richard T. Desmond). 4.1 Interface Peptides Defined. 4.2 Unmodified Peptides. 4.3 Modified Peptides. 4.4 Summary/Perspective. References. 5 Inhibition of Protein-Protein Interactions by Peptide Mimics (Jorge Becerril, Johanna M. Rodriguez, Pauline N. Wyrembak, and Andrew D. Hamilton). 5.1 Introduction. 5.2 Inhibition of Calmodulin. 5.3 Inhibition of HIV-1 Fusion. 5.4 Inhibition of the Nuclear Estrogen Receptor. 5.5 Inhibition of the Bcl-xL/Bak Interaction. 5.6 Inhibition of the p53/MDM2 Interaction. 5.7 Miscellaneous Protein Targets. 5.8 Conclusion. References. 6 Discovery of Inhibitors of Protein-Protein Interactions by Screening Chemical Libraries (Carlos García-Echeverría). 6.1 Introduction. 6.2 Screening Strategies to Identify and Develop Antagonists of Protein-Protein Interactions. 6.3 Mimetics of Common Protein Structure Motifs and Structure-based Design of Peptidomimetics. 6.4 Conclusions and Outlook. References. PART III TECHNIQUES. 7 High-throughput Methods of Chemical Synthesis Applied to the Preparation of Inhibitors of Protein-Protein Interactions (Annaliese K. Franz, Jared T. Shaw, and Yuchen Tang). 7.1 Introduction. 7.2 Survey of High-throughput Organic Synthesis. 7.3 Synthesis of 'Peptide-Inspired' Compounds and Libraries. 7.4 Synthesis of 'Natural Product-Inspired' Compounds and Libraries. 7.5 Diversity Oriented Synthesis (DOS) in the Discovery of PPI Inhibitors. 7.6 Summary and Outlook. References. 8 In Silico screening (F.J. Luque, and Xavier Barril). 8.1 Introduction. 8.2 Methods for Virtual Ligand Screening. 8.3 Binding Site Characterization. 8.4 Case Studies. 8.5 Outlook and Conclusions. References. 9.1 In Vitro Screening: Screening by Nuclear Magnetic Resonance (Ernest Giralt). 9.1.1 Saturation Transfer Difference (STD). 9.1.2 STD in Fragment-based Drug Design. 9.1.3 Chemical Shift Perturbation (CSP). 9.1.4 19F-NMR in Molecular Recognition Studies. References. 9.2 In Vitro Screening: Methods of High-throughput Screening (Wenjiao Song and Qing Lin). 9.2.1 Introduction. 9.2.2 Statistical Evaluation of the HTS Assay Performance. 9.2.3 Biochemical Assays. 9.2.4 Cell-based Assays. 9.2.5 Conclusion. References. PART IV CASE STUDIES. 10 Case Study: Inhibitors of the MDM2-p53 Protein-Protein Interaction (Sanjeev Shangary, Denzil Bernard, and Shaomeng Wang). 10.1 MDM2-p53 Protein-Protein Interaction: A Case Study. 10.2 Regulation of p53 by the MDM2-p53 Protein-Protein Interaction. 10.3 Structural Basis of the MDM2-p53 Interaction. 10.4 Design of p53-based Peptides. 10.5 Design of Nonpeptidic Small-Molecule Inhibitors of the MDM2-p53 Interaction. 10.6 Challenges in the Design of Small Molecule Inhibitors of the MDM2-p53 Interaction. 10.7 Reactivation of p53 by Inhibitors of the MDM2-p53 Interaction. 10.8 Development of MDM2 Inhibitors and New Anticancer Drugs. 10.9 Concluding Remarks. References. 11 Case Study: The Discovery of Potent LFA-1 Antagonists (Tom Gadek). 11.1 Introduction. 11.2 Structural, Molecular and Cellular Biologies of LFA-1. 11.3 The Search for Small Molecule LFA-1 Antagonists. 11.4 Screening Assays. 11.5 Lead Identification and Optimization. 11.6 Protein and Small Molecule Structure Activity Relationships (PSAR) in the LFA-1/ICAM-1 Interaction. 11.7 Summary. References. Index.
Preface. List of Contributors. PART I PRINCIPLES. 1 The Discovery and Characterization of Protein-Protein Interactions (C.W. Bertoncini, A. Higueruelo, and X. Salvatella). 1.1 Introduction. 1.2 Techniques to Identify Protein-Protein Interactions. 1.3 Techniques to Characterize Protein-Protein Interactions. 1.4 Structure and Dynamics of Protein Complexes. 1.5 Protein-Protein Complexes as Therapeutic Targets. 1.6 Conclusions. References. 2 Biophysics of Protein-Protein Interactions (Irene Luque). 2.1 Introduction. 2.2 Intermolecular Forces in Protein Recognition. 2.3 Basic Binding Thermodynamics. 2.4 Thermodynamically Driven Drug Design. 2.5 Measurement of Binding Energetics. 2.6 Structure-based Calculation of Protein Binding Energetics. 2.7 Interfacial Water Molecules in Protein Recognition. 2.8 The Linkage Between Binding and Conformational Equilibrium in Proteins. References. PART II APPROACHES. 3 On the Logic of Natural Product Binding in Protein-Protein Interactivity (James J. La Clair). 3.1 Introduction. 3.2 Structural Logic. 3.3 Functional Logic. 3.4 The Need for Programmers. 3.5 Compiling the NPPI Mapper. References. 4 Interface peptide inhibitors of PPIs (Mark W. Peczuh, and Richard T. Desmond). 4.1 Interface Peptides Defined. 4.2 Unmodified Peptides. 4.3 Modified Peptides. 4.4 Summary/Perspective. References. 5 Inhibition of Protein-Protein Interactions by Peptide Mimics (Jorge Becerril, Johanna M. Rodriguez, Pauline N. Wyrembak, and Andrew D. Hamilton). 5.1 Introduction. 5.2 Inhibition of Calmodulin. 5.3 Inhibition of HIV-1 Fusion. 5.4 Inhibition of the Nuclear Estrogen Receptor. 5.5 Inhibition of the Bcl-xL/Bak Interaction. 5.6 Inhibition of the p53/MDM2 Interaction. 5.7 Miscellaneous Protein Targets. 5.8 Conclusion. References. 6 Discovery of Inhibitors of Protein-Protein Interactions by Screening Chemical Libraries (Carlos García-Echeverría). 6.1 Introduction. 6.2 Screening Strategies to Identify and Develop Antagonists of Protein-Protein Interactions. 6.3 Mimetics of Common Protein Structure Motifs and Structure-based Design of Peptidomimetics. 6.4 Conclusions and Outlook. References. PART III TECHNIQUES. 7 High-throughput Methods of Chemical Synthesis Applied to the Preparation of Inhibitors of Protein-Protein Interactions (Annaliese K. Franz, Jared T. Shaw, and Yuchen Tang). 7.1 Introduction. 7.2 Survey of High-throughput Organic Synthesis. 7.3 Synthesis of 'Peptide-Inspired' Compounds and Libraries. 7.4 Synthesis of 'Natural Product-Inspired' Compounds and Libraries. 7.5 Diversity Oriented Synthesis (DOS) in the Discovery of PPI Inhibitors. 7.6 Summary and Outlook. References. 8 In Silico screening (F.J. Luque, and Xavier Barril). 8.1 Introduction. 8.2 Methods for Virtual Ligand Screening. 8.3 Binding Site Characterization. 8.4 Case Studies. 8.5 Outlook and Conclusions. References. 9.1 In Vitro Screening: Screening by Nuclear Magnetic Resonance (Ernest Giralt). 9.1.1 Saturation Transfer Difference (STD). 9.1.2 STD in Fragment-based Drug Design. 9.1.3 Chemical Shift Perturbation (CSP). 9.1.4 19F-NMR in Molecular Recognition Studies. References. 9.2 In Vitro Screening: Methods of High-throughput Screening (Wenjiao Song and Qing Lin). 9.2.1 Introduction. 9.2.2 Statistical Evaluation of the HTS Assay Performance. 9.2.3 Biochemical Assays. 9.2.4 Cell-based Assays. 9.2.5 Conclusion. References. PART IV CASE STUDIES. 10 Case Study: Inhibitors of the MDM2-p53 Protein-Protein Interaction (Sanjeev Shangary, Denzil Bernard, and Shaomeng Wang). 10.1 MDM2-p53 Protein-Protein Interaction: A Case Study. 10.2 Regulation of p53 by the MDM2-p53 Protein-Protein Interaction. 10.3 Structural Basis of the MDM2-p53 Interaction. 10.4 Design of p53-based Peptides. 10.5 Design of Nonpeptidic Small-Molecule Inhibitors of the MDM2-p53 Interaction. 10.6 Challenges in the Design of Small Molecule Inhibitors of the MDM2-p53 Interaction. 10.7 Reactivation of p53 by Inhibitors of the MDM2-p53 Interaction. 10.8 Development of MDM2 Inhibitors and New Anticancer Drugs. 10.9 Concluding Remarks. References. 11 Case Study: The Discovery of Potent LFA-1 Antagonists (Tom Gadek). 11.1 Introduction. 11.2 Structural, Molecular and Cellular Biologies of LFA-1. 11.3 The Search for Small Molecule LFA-1 Antagonists. 11.4 Screening Assays. 11.5 Lead Identification and Optimization. 11.6 Protein and Small Molecule Structure Activity Relationships (PSAR) in the LFA-1/ICAM-1 Interaction. 11.7 Summary. References. Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
